Objective:To study the efficiency and safety of pemetrexed combined with platinum chemotherapy in the treatment process of advanced lung adenocarcinoma. Methods:200 patients with advanced lung adenocarcinoma treated in our hospital were considered as study object. They were divided into two groups, 102 patients were treated with docetaxel and cisplatin (control group), while 98 patients were used with pemetrexed and cisplatin for treatment (observation group). The clinical efficacy between the two groups was observed and compared. Results:(1) Before treatment, there was no obvious difference between the two groups including carcino-embryonic antigen (CEA), cancer antigen 125 (CA125), cytokeratin fragment antigen 21-1 (CYFRA21-1) and the scores about physical function, fatigue, nausea and vomiting, insomnia, loss of appetite, overall quality of life(P>0.05); After treatment, the index including CEA, CA125, CYFRA21-1 and the scores about fatigue, nausea and vomiting, insomnia, loss of appetite were significantly lower in observation group compared with the control group(P>0.05), while the scores about physical function and overall quality of life were significantly higher in observation group than control group(P>0.05). (2) The effective rate in the observation group was significantly higher than the control group(P<0.05), and the progression free survival and overall survival in the observation group were significantly higher than the control group with increased adverse reaction(P<0.05). Conclusion:Pemetrexed combined with platinum chemotherapy drugs is used in the treatment process of advanced lung cancer. It can reduce the level of CEA, CA125, CYFRA21-1 with improved quality of life. The method is safe with better treatment effect. |
[1] 周亚星,杨锫,刘英姿,等.NF-κB及PXR基因多态对非小细胞肺癌铂类药物治疗的影响[J].中南大学学报:医学版,2016,41(3):233-237.
[2] 李健,郑琳,戚永超,等.完全与杂交式胸腔镜肺叶切除治疗早期非小细胞肺癌的疗效比较[J].现代医学,2017,6(2):234-238.
[3] 唐艳,吴芳,胡春宏.RUNX3基因启动子甲基化与早期非小细胞肺癌的预后[J].中南大学学报:医学版,2011,36(7):650-654.
[4] 凌华晃,李涛,吴祥成,等.培美曲塞二钠联合奈达铂治疗老年晚期肺腺癌的临床疗效及安全性观察[J].中国全科医学,2013,16(7):2506-2508.
[5] 周彩存,吴一龙,孙燕,等.组织学类型对培美曲塞治疗中国晚期非小细胞肺癌二线及一线后维持治疗患者的综合分析[J].中华肿瘤杂志,2014,36(1):29-33.
[6] 陈惕.奈达铂联合培美曲塞二钠治疗晚期肺腺癌的临床疗效及安全性[J].实用癌症杂志,2015,6(3):435-437.
[7] 王凤庭.培美曲塞二钠联合奈达铂治疗晚期非小细胞肺癌[J].肿瘤基础与临床,2014,12(6):485-486.
[8] 曹运锋,石凡英,郭春辉,等.培美曲塞和吉西他滨分别联合奈达铂治疗晚期肺腺癌的疗效及安全性比较[J].国际呼吸杂志,2016,36(11):810-813.
[9] 杨艳荣.培美曲塞与吉西他滨联合顺铂治疗晚期肺腺癌疗效及安全性比较[J].新乡医学院学报,2015,32(12):1103-1105.
[10] 段惠洁,顾国民,王秀丽,等.培美曲塞联合奈达铂一线方案治疗晚期肺腺癌的临床研究[J].肿瘤防治研究,2014,41(1):61-64.
[11] 康欢,胡蔚,康艳红,等.多种肿瘤标志物联合检测在肺癌诊断中的实用价值[J].现代医学,2012,40(6):706-708.
[12] 杨新杰,张卉,张权,等.培美曲塞或吉西他滨联合顺铂一线治疗晚期非小细胞肺癌的临床随机对照研究[J].中华肿瘤防治杂志,2012,19(6):38-41.
[13] 冯晓云,严玲玲,陆志斌.探讨肺癌患者CEA、SCC-Ag和SF经Logistic回归及ROC曲线综合分析的诊断价值[J].现代医学,2016,8(10):1378-1382.
[14] ZHAO J,ZHAO M,JIN B,et al.Tumor response and survival in patients with advanced non-small-cell lung cancer:the predictive value of chemotherapy-induced changes in fibrinogen[J].BMC Cancer,2012,12(6):330-338.
[15] SZTURMOWICZ M,RUDZIN'SKI P,KACPRZAK A,et al.Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer[J].Pneumonol Alergol Pol,2014,82(5):422-429.
[16] 雷旦生,裴锋,喻晶,等.组织多肽抗原联合ProGRP、CEA、NSE、SCC、CYFRA21-1在肺癌诊治中的价值[J].肿瘤防治研究,2015,42(5):488-492. |
